30 June 2022
Microsaic Systems PLC
("Microsaic" or "the Company")
Result of Annual General Meeting
The Company is pleased to announce that at its Annual General Meeting held earlier today, all five ordinary resolutions put to the meeting were duly passed. The special resolution relating to the disapplication of pre-emption rights did not achieve the required 75% of votes cast and therefore was not passed.
The voting results of the AGM were as follows:
| No. | Resolution | For* | Against |
| 1 | To approve the annual report and accounts for the year ended 31 December 2021. | 65.2% | 34.8 % |
| 2 | To re-appoint and authorise the remuneration of the Company's auditor. | 100.0% | 0.0% |
| 3 | To re-elect Bob Moore Burton as a director. | 99.8% | 0.2% |
| 4 | To re-elect Dr Nigel Burton as a director. | 65.2% | 34.8% |
| 5 | To give the directors a general authority to allot shares in the Company and to grant rights to subscribe for, or to convert any security into, shares in the Company. | 99.4% | 0.6% |
| 6 | To empower the directors to allot equity securities for cash. | 63.4% | 36.6% |
* Includes proxies received to be voted at the discretion of the Chairman.
| Enquiries: | |
| Microsaic Systems plc Gerry Brandon Chairman
| +44 (0)734 0055 648 |
| Singer Capital Markets | +44 (0)20 7496 3000 |
| Aubrey Powell / Tom Salvesen / George Tzimas
| |
| Turner Pope Investments (TPI) Limited (Broker) Andy Thacker / James Pope | +44 (0) 20 3657 0050 |
| | |
About Microsaic
Microsaic develops and commercialises micro-engineering chip-based mass spectrometry equipment. Microsaic has a robust patent portfolio in cutting-edge technology purpose built for "Industry 4.0" which enables analytical detection and characterisation at the point-of-need, whether within a human health environment, conventional laboratory setting, or within a bioprocessing facility for continuous mass spectrometer detection and monitoring of data at any step in the process workflow, or in frontline environmental monitoring
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
